FLGT Stock Cash Flow Statements

Fulgent Genetics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Fulgent Genetics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31

cash flow from operating activities:
net income from consolidated operations	-19,256,000	-11,899,000	-6,190,000	-14,694,000	-9,090,000	-13,846,000	-134,334,000	-13,466,000	-11,590,000	-15,849,000	-24,076,000	1,343,000	11,099,000	153,557,000	103,677,000	122,224,000
adjustments to reconcile net income to net cash from operating activities:
equity-based compensation	10,039,000	10,550,000	10,408,000	10,920,000	11,635,000	11,518,000	11,432,000	10,902,000	10,323,000	10,265,000	10,022,000	8,972,000	8,030,000	5,616,000	5,020,000	4,374,000	3,526,000	2,962,000	3,003,000	3,150,000	1,080,000	924,000	938,000	951,000	737,000	583,000	598,000	588,000	573,000	545,000	581,000	549,000	424,000	565,000	535,000
depreciation and amortization	6,054,000	5,919,000	6,192,000	5,920,000	6,153,000	6,663,000	6,533,000	6,419,000	6,312,000	6,879,000	9,802,000	9,820,000	8,345,000	4,695,000	3,491,000	3,173,000														516,000	473,000	438,000	405,000	412,000	420,000
adjustment for credit losses	2,591,000	2,075,000		947,000
noncash lease expense	362,000	350,000	477,000	604,000	1,169,000	1,510,000	1,517,000	1,627,000	1,707,000	1,561,000	1,602,000	1,601,000	1,233,000	477,000	472,000	384,000	216,000	82,000	64,000	125,000	112,000	108,000	107,000	105,000	101,000	100,000
(gain) loss on disposal of fixed asset	0	-2,000								-179,000
amortization of discount of marketable securities	-1,406,000	-1,658,000		-1,335,000	-1,486,000	-1,184,000
deferred taxes	-113,000	-133,000	-364,000	-2,358,000	-457,000	-557,000	502,000	19,382,000	-3,218,000	-5,200,000	-3,346,000	2,705,000	-2,142,000	-5,497,000	-1,614,000	-3,519,000	-2,269,000	-786,000	-692,000				0					-352,000	-101,000	-434,000
unrecognized tax benefits	137,000	137,000	-1,762,000	31,000			-3,577,000				8,010,000	96,000	520,000	485,000	191,000	29,000	32,000	96,000	-12,000
net realized loss on marketable securities			52,000	71,000	291,000	580,000
impairment loss
other	12,000	21,000	-21,000	19,000	7,000	-12,000	8,000	-49,000			12,000	-6,000	-32,000	15,000	7,000	-14,000	0	-8,000	15,000	-1,000	36,000	-42,000	11,000	3,000	66,000	-28,000	26,000	-20,000	10,000	28,000
changes in operating assets and liabilities:
trade accounts receivable	-8,257,000	-4,524,000	-13,325,000	-1,585,000	-2,877,000	1,484,000	-5,208,000	-12,062,000	10,327,000	9,331,000	44,424,000	22,412,000	34,726,000	-32,924,000		32,543,000	67,055,000	-34,595,000
income tax	-34,793,000	1,761,000
other current and long-term assets	-458,000	804,000	775,000	-4,673,000	-1,033,000	5,130,000	2,304,000	888,000	-2,135,000	-1,629,000	-8,059,000	5,576,000	-4,816,000	2,962,000	9,890,000	3,939,000	3,084,000	-9,109,000	-1,973,000	-15,349,000	-2,903,000	-924,000	-76,000	267,000	119,000	64,000
accounts payable	386,000	-658,000	-808,000	2,278,000	1,841,000	-245,000	129,000	-2,578,000	-2,592,000	-1,855,000	6,992,000	-22,073,000	-12,368,000	2,110,000	-3,204,000	1,254,000	-4,000,000	-6,256,000	7,942,000	12,391,000	377,000	1,907,000	-238,000	33,000	-203,000	79,000	277,000	1,169,000	-1,562,000	218,000	-377,000	569,000	-122,000	-433,000
contract liabilities	-144,000	582,000	-732,000	223,000												965,000	-7,046,000	-12,616,000
customer deposits	-99,000	83,000	681,000	632,000
accrued liabilities and other liabilities	5,203,000	-7,485,000	628,000	-1,827,000	-2,813,000	51,000	14,531,000	4,195,000	4,596,000	-9,114,000	-18,394,000	-13,169,000	8,495,000	-8,231,000	14,034,000	-4,037,000			10,486,000	21,499,000
operating lease liabilities	-355,000	-354,000	-483,000	-601,000				-1,618,000									-211,000	-82,000	-64,000	-120,000	-104,000	-101,000	-99,000	-122,000	-95,000	-93,000
net cash from operating activities	-30,171,000	-4,431,000	25,018,000	-15,509,000	4,285,000	7,266,000	14,933,000	10,240,000	9,737,000	-7,907,000	33,207,000	20,776,000	11,126,000	188,411,000	77,086,000	152,201,000	76,111,000	233,179,000		9,415,000	-4,409,000	1,366,000									-1,241,000	500,000	1,365,000	707,000	1,254,000
cash flow from investing activities:
maturities of marketable securities	60,230,000	32,445,000	71,787,000	117,935,000	64,623,000	95,450,000	131,668,000	118,043,000	117,439,000	141,408,000	100,821,000	61,281,000	42,672,000	27,760,000	22,326,000	26,978,000	20,080,000	14,458,000	6,800,000	5,792,000	2,401,000	4,926,000	4,750,000	8,100,000	7,900,000	3,600,000	8,609,000	7,704,000	5,806,000	5,850,000	5,785,000	1,800,000	2,600,000	1,000,000
proceeds from sale of marketable securities			2,742,000	25,929,000	18,696,000	56,903,000					6,769,000	0	0	133,407,000	29,940,000	104,113,000			9,023,000
proceeds from sale of fixed assets	0	2,000	0	38,000	17,000	258,000	335,000	22,000	220,000	198,000	172,000	222,000	4,000	14,000	41,000	9,000	0	13,000
purchase of marketable securities			-98,206,000	-115,380,000	-63,088,000	-195,741,000	-148,313,000	-93,064,000	-106,611,000	-143,926,000	-160,715,000	-11,779,000	-115,355,000	-130,133,000	-186,551,000	-99,132,000	-205,337,000	-219,470,000	-310,796,000	-1,176,000	-4,395,000	-7,992,000	-40,231,000	-1,668,000	-4,190,000	-5,988,000	-11,022,000	-1,695,000	-6,787,000	-4,683,000	-6,407,000	-1,670,000	-802,000	-2,780,000
purchases of fixed assets	-6,826,000	-4,718,000	-3,778,000	-19,537,000	-12,944,000	-4,056,000	-3,106,000	-4,923,000	-12,144,000	-2,034,000	-4,722,000	-5,435,000	-3,258,000	-5,360,000	-5,983,000	-3,402,000	-2,935,000	-11,492,000	-23,794,000	-10,129,000	-411,000	-796,000	-461,000	-88,000	-499,000	-134,000	-123,000	-1,047,000	-36,000	-1,116,000	-1,141,000	-237,000	-1,427,000	-90,000	-409,000
net cash from investing activities	53,404,000	27,729,000	-27,455,000	8,985,000	7,304,000	-47,186,000	24,270,000	20,078,000	-1,096,000	-4,354,000	-92,599,000	44,289,000	-213,692,000	688,000	-140,259,000	-34,793,000	-155,005,000	-216,491,000	-318,767,000	-1,404,000	-2,405,000	-3,862,000	-36,079,000	6,344,000	3,211,000	-2,522,000	-2,536,000	4,962,000	-1,527,000	51,000	-1,763,000	-2,568,000	4,152,000	-1,870,000	-39,416,000
cash flow from financing activities:
repurchase of common stock	-2,205,000	-8,679,000	0	0	0	-225,000	-22,862,000				-29,058,000	-34,702,000
common stock withholding for employee tax obligations	-345,000	-1,887,000	-242,000	-431,000	-544,000	-1,682,000	-1,114,000	-517,000	-232,000	-869,000	-316,000	-522,000	-436,000	-494,000	-688,000	-2,915,000
repayment of notes payable	-1,000	-470,000	0	-1,000	-464,000	-765,000	-1,837,000	-1,630,000			0	1,000	7,000	-375,000
principal paid for finance lease	-87,000	-136,000	-136,000	-135,000	-138,000	-135,000		-129,000	-231,000	-232,000		-239,000	-149,000	-81,000	-4,000
net cash from financing activities	-2,638,000	-11,172,000	-327,000	-567,000	-1,146,000	-2,807,000	-25,951,000	-4,474,000	-16,259,000	-1,101,000	-29,593,000	-35,462,000	-11,152,000	-934,000	13,154,000	-2,989,000	27,893,000	47,347,000	218,903,000	42,571,000	-59,000	-164,000	27,639,000	1,127,000	5,000	4,000	5,000	1,000	7,000	2,000	4,000	4,000			37,854,000
effect of exchange rate changes on cash and cash equivalents	4,000	11,000	-134,000	157,000	-9,000	-69,000	145,000	-116,000	-206,000	28,000	-279,000	387,000	-571,000	10,000	36,000	-3,000			3,000	18,000	2,000	-3,000	-1,000	-17,000	-14,000	15,000	0	-23,000	-43,000	22,000	12,000
net increase in cash, cash equivalents, and restricted cash	20,599,000	12,137,000	-2,898,000
cash, cash equivalents, and restricted cash at beginning of period	0	55,279,000	0
cash, cash equivalents, and restricted cash at end of period	20,599,000	67,416,000	-2,898,000
supplemental disclosures of cash flow information:
cash and cash equivalents	20,599,000	67,281,000	-2,898,000
restricted cash	0	135,000	0
total cash, cash equivalents, and restricted cash	20,599,000	67,416,000	-2,898,000
income taxes paid	32,749,000	54,000	946,000	24,739,000	596,000	1,307,000	563,000	62,000	956,000	1,680,000	12,000	1,199,000	54,547,000	435,000	67,529,000	49,560,000	119,947,000	33,000	20,584,000	0			0	0			0	0			0	1,000
interest paid	-17,000	61,000	50,000	10,000				21,000
supplemental disclosures of non-cash investing and financing activities:
purchases of fixed assets in accounts payable	259,000	2,322,000	-682,000	-2,295,000	44,000	4,739,000	511,000	-2,437,000	1,188,000	2,537,000	1,299,000	-468,000	104,000	2,054,000	-1,204,000	1,537,000	-59,000	801,000	580,000	2,325,000			-323,000
operating lease right-of-use assets obtained in exchange for lease liabilities			0	12,000			0	0			0				91,000	941,000	397,000	368,000	9,000	0			0
operating lease right-of-use assets reduced due to lease modification and termination			0	0
sale of fixed assets in other receivable						11,000
cash flow from operating activities
goodwill impairment loss
(adjustment) benefit from credit losses
loss on disposal of fixed asset			103,000	45,000			-124,000	418,000			202,000	-9,000	59,000	250,000	71,000	181,000	375,000	223,000	320,000				0	0				33,000	4,000	51,000		0
amortization of (discount) premium of marketable securities								-1,190,000	-714,000	-478,000
impairment of available-for-sale debt securities			0
cash flow from investing activities
purchase of preferred stock of privately held company											0
contingent consideration payout related to a business acquisition											0	0	0	-10,000,000
acquisition of businesses, net of cash acquired											-34,924,000	0			0	-43,359,000
cash flow from financing activities
repayment of investment margin loan								0
proceeds from exercise of stock options							0	0			12,000	0	3,000	16,000	1,000	17,000	24,000	44,000	2,000	62,000	28,000	12,000	12,000	17,000	5,000	4,000	5,000	1,000	7,000	2,000	4,000	4,000
supplemental disclosures of cash flow information
supplemental disclosures of non-cash investing and financing activities
stock consideration in a business combination
maturities of marketable securities in ither current assets
purchases of fixed assets in notes payable											0	0	0	3,833,000
finance lease right-of-use assets obtained in exchange for lease liabilities											0
operating lease liabilities removed due to purchasing underlying assets			0
finance lease right-of-use assets reduced due to lease modification and termination								0
prepaid income tax
net decrease in cash and cash equivalents					10,434,000	-42,796,000																-2,663,000
cash and cash equivalents at beginning of period					0	97,473,000	0	0	0	79,506,000	0	0	0	164,894,000	0	0	0	87,426,000	0	0	0	11,965,000
cash and cash equivalents at end of period					10,434,000	54,677,000	13,397,000	25,728,000	-7,824,000	66,172,000	-89,264,000	29,990,000	-214,289,000	353,069,000	-49,983,000	114,416,000	-51,000,000	151,461,000	34,395,000	50,600,000	-6,871,000	9,302,000
gain for credit losses						-2,497,000
gain on disposal of fixed asset						183,000
operating and finance lease liabilities						-1,512,000				-1,526,000	-1,500,000	-1,652,000	-1,202,000	-477,000	-474,000
cash paid for interest						439,000
purchases of marketable securities in other current liabilities										3,519,000
operating lease right-of-use assets reduced due to lease termination						57,000
provision (gain) for credit losses
amortization (discount) of premium of marketable securities
net income on marketable securities											66,000	9,000	104,000	513,000	591,000
gain in equity-method investments
income tax payable											-427,000	-2,378,000	-49,398,000	51,376,000	-17,088,000	-8,524,000	-94,123,000	67,203,000	38,692,000	14,627,000	-58,000	34,000	-36,000
purchases of intangible assets
purchase of redeemable preferred stock															0
proceeds from public offerings of common stock, net of issuance costs															13,849,000				203,898,000				27,648,000
proceeds from noncontrolling interest															0	0
principal paid for finance leases
re-payment for the margin account
net increase in cash and cash equivalents							13,397,000			-13,334,000	-89,264,000	29,990,000	-214,289,000	188,175,000	-49,983,000	114,416,000	-51,000,000	64,035,000	34,395,000	50,600,000
maturities of marketable securities in other current assets
operating lease right-of-use assets reduced due to lease modification or termination
finance lease right-of-use assets reduced due to lease modification or termination
contingent consideration for business acquisition included in current liabilities
public offerings costs included in accounts payable																	-20,000	50,000	-15,000	372,000	1,000	1,000	-2,000
allowance for credit losses at beginning of year
impact of asu 2016-13 adoption
current period (gain) provision
write-downs
allowance for credit losses at end of year
benefit from credit losses								-2,347,000	-1,871,000	-113,000	7,340,000	6,522,000	7,160,000	11,574,000	4,824,000	848,000	2,195,000	1,064,000
investment in private equity securities													0	-15,000,000
purchase of marketable securities in other current liabilities																						500,000
amortization of premium of marketable securities											537,000	1,007,000	1,313,000	1,910,000	2,106,000	2,319,000	1,868,000	1,303,000	530,000	109,000	113,000	105,000	54,000	8,000	7,000	37,000	58,000	79,000	78,000	82,000	84,000	90,000	101,000	95,000
equity loss in investee																			-143,000	189,000	193,000	249,000	174,000	175,000	149,000	279,000	234,000	210,000	246,000	245,000	247,000
(gain) loss in equity-method investments
investment in equity-method investees
borrowing under margin account																	29,000	29,000
public offerings proceeds in other receivable included in other current assets
current period provision
gain on equity method investment
contingent consideration for business acquisition included in other current liabilities
accounts receivable																			-93,923,000	-77,120,000	-7,541,000	104,000	-1,427,000	220,000	-1,046,000	1,414,000	23,000	-1,003,000	-277,000	-713,000	-545,000	581,000	415,000	-237,000
gain on equity-method investments
customer deposit																-3,817,000	27,903,000	16,816,000
public offerings proceeds included in other current assets
testing services by payor
insurance
institutional
patient
total revenue
adjustments to reconcile net income to net cash provided (used in) by operating activities:
holding loss on equity securities																	15,000	345,000
proceeds from (payment for) public offerings of common stock, net of issuance costs																	27,869,000	47,787,000
operating lease right-of-use assets reduced due to lease modification																	0	185,000
net income																		200,691,000	166,307,000	46,638,000	3,321,000	-1,956,000	-296,000	1,462,000	331,000	-1,908,000	-2,053,000	-595,000	-1,049,000	-1,910,000	-1,624,000	-1,093,000	-25,000	232,000	813,000
depreciation																		1,922,000	1,122,000	722,000	549,000	569,000	558,000	503,000	511,000	535,000	538,000	547,000
other current liabilities																		3,924,000
repurchases of capital stock																		-513,000	-16,000	0	0	-46,000
benefit from bad debt																			729,000	306,000	14,000	121,000	152,000				79,000	0	182,000	48,000	149,000				103,000
impairment loss in equity method investments
net cash from operations																							-116,000	3,903,000	675,000	1,055,000		-105,000	-57,000	-1,291,000
purchase of equipment contributed to equity-method investee
investment in equity method investee																			0
operating lease liabilities removed due to purchasing of underlying assets
impairment loss in equity method investment
proceeds from disposal of fixed assets
purchase of equipment contributed to equity method investee																											0	0			0
payment of public offering costs																					-87,000	-130,000
accrued liabilities and other current liabilities																						268,000
fixed assets included in accounts payable																						43,000			-40,000	45,000	12,000	-938,000	1,005,000	6,000	115,000	-44,000	932,000	11,000	1,076,000
accrued liabilities																								222,000	-13,000	-7,000	199,000	-954,000	1,130,000	158,000	115,000	-95,000	768,000	310,000
net increase in cash																															-2,988,000	-1,995,000	4,739,000	-1,163,000	-308,000
cash balance at beginning of period																								0	0	6,736,000	0	0	0	6,490,000	0	0	0	7,897,000	0
cash balance at end of period																								11,357,000	3,877,000	5,288,000	-1,753,000	4,835,000	-1,620,000	5,274,000	-2,988,000	-1,995,000	4,739,000	6,734,000	-308,000
net decrease in cash																									3,877,000	-1,448,000		4,835,000	-1,620,000	-1,216,000
deferred income taxes																																			-171,000
other current assets																											-124,000	193,000	147,000	-125,000	9,000	-721,000	-482,000	-343,000
taxes payable																															0	-1,000	-288,000	165,000
cash from operating activities
sale of marketable securities																															0	0
payment of initial public offering costs																															0	0
income from discontinued operations																																			0
income from continuing operations																															-1,624,000	-1,093,000	-25,000	232,000	813,000
fair value adjustment recorded upon issuance of class d-2 preferred units
cash from continuing operations																															-1,241,000	500,000	1,365,000	707,000	1,254,000
cash from discontinued operations																																			0
proceeds from issuance of common stock, net of offering costs
cash distributed in split-off of pharma business																																			0
distribution to class d-1 preferred unitholder
proceeds from issuance of class d-2 preferred units
repurchase and retirement of class d-1 preferred and class d common units																																			-1,000
tax distribution to class d common and preferred unitholders
initial public offering costs included in accounts payable and accrued expenses
return of capital contribution
issuance costs of class d-2 preferred units
tax distribution to class d common and preferred unitholders in other current liabilities
deferred initial public offering costs included in accounts payable
equity in net income of affiliate
operating expenses:
research and development
general and administrative
total operating expenses
operating income
other income
income
income allocated to class p common units - profit interests
income allocated to class p common units
income allocated to class p preferred units
income per class p common units - profit interests, basic and diluted
income per class p common units, basic and diluted
income per class p preferred units, basic and diluted
weighted-average class p common units - profit interests, basic and diluted
weighted-average class p common units, basic and diluted
weighted-average class p preferred units, basic and diluted
excess tax benefits																																		-59,000
capital contributions
supplemental cash flow information:
weighted-average class p common units - profits interests - outstanding, basic and diluted
weighted-average class p preferred units outstanding, basic and diluted
gain on disposal of fixed assets
amortization of premium on marketable securities
fair value adjustment recorded upon issuance of d-2 preferred units																																			0
income taxes payable
issuance of class d-2 preferred units, net of issuance costs
recapitalization
increase in accounts receivable
increase in other current assets
increase in accounts payable
increase in accrued liabilities
proceeds from issuance of d-2 units
interest and other income

We provide you with 20 years of cash flow statements for Fulgent Genetics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Fulgent Genetics stock. Explore the full financial landscape of Fulgent Genetics stock with our expertly curated income statements.

The information provided in this report about Fulgent Genetics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.